Bupropion is NOT a first-line treatment for anxiety—switch to an SSRI or SNRI, or add one as adjunctive therapy
The patient is on the wrong medication for anxiety. Bupropion is FDA-approved for depression and smoking cessation, but not for anxiety disorders 1. While it can be activating and may even worsen anxiety symptoms, particularly at higher doses 2, the evidence for its anxiolytic effects remains limited and inconsistent.
Why Bupropion Alone is Insufficient for Anxiety
Bupropion is a norepinephrine-dopamine reuptake inhibitor with stimulating properties that can provoke anxiety, especially in patients without depression 2. The FDA label explicitly warns about neuropsychiatric adverse events including anxiety, agitation, and panic attacks 1. Clinical trials suggest bupropion may reduce anxiety symptoms primarily in depressed patients with comorbid anxiety, but it shows no clear efficacy for primary anxiety disorders 2, 3.
Recent systematic reviews indicate that while bupropion may provide some improvement in anxiety symptoms when depression is present, SSRIs demonstrate a modest but consistent advantage, particularly in patients with high baseline anxiety 3. The evidence is low-certainty because anxiety was typically a secondary or exploratory outcome rather than a primary endpoint 3.
Recommended Treatment Algorithm
First-Line Approach: Switch to an SSRI or SNRI
Switch from bupropion 150 mg to an SSRI (sertraline, escitalopram, or paroxetine) or SNRI (venlafaxine or duloxetine). These are the evidence-based first-line treatments for anxiety disorders 4.
- Sertraline: Start 25-50 mg daily, increase to 200 mg daily as tolerated 5
- Escitalopram/Citalopram: Start 10 mg daily, increase to 20-40 mg daily 5
- Venlafaxine: Start 50-75 mg daily, increase to 75-225 mg daily 6
When switching, taper bupropion over 10-14 days to minimize withdrawal symptoms 5. Start the SSRI/SNRI at a low "test dose" to minimize initial anxiety or agitation, which is a known side effect 4.
Alternative: Add an SSRI/SNRI as Adjunctive Therapy
If there are compelling reasons to continue bupropion (e.g., concurrent depression with good response, smoking cessation needs, or avoidance of sexual side effects), add an SSRI or SNRI as adjunctive therapy 7, 8.
- Combination therapy with bupropion plus an SSRI/SNRI has shown efficacy in clinical practice, with 56% response rates in one study 7
- This approach is particularly useful when bupropion has provided benefit for depression or other symptoms but anxiety persists
- Monitor closely for serotonin syndrome when combining, though the risk is relatively low with careful dosing 5
Consider Buspirone as Second-Line Adjunct
If SSRIs/SNRIs are contraindicated or not tolerated, buspirone can be added to bupropion 5:
- Start 5 mg twice daily, increase to maximum 20 mg three times daily
- Takes 2-4 weeks to become effective
- Useful for mild to moderate anxiety without sedation
Avoid Benzodiazepines for Chronic Management
While benzodiazepines provide rapid anxiety relief, they should be avoided for long-term management due to dependence risk, cognitive impairment, and increased seizure risk when combined with bupropion 5, 1.
Critical Safety Considerations
Bupropion lowers the seizure threshold 1. The maximum dose is 300 mg daily, and it's contraindicated in patients with seizure disorders, eating disorders, or those undergoing abrupt discontinuation of alcohol or benzodiazepines 1. If the patient is using alcohol heavily or taking benzodiazepines, address this before adjusting treatment.
Monitor for neuropsychiatric adverse events including worsening anxiety, agitation, panic attacks, and suicidal ideation, especially during the first few weeks of any medication change 1. This is particularly important in patients under 24 years old.
Timeline and Monitoring
- Allow 4-8 weeks for full therapeutic effect of any antidepressant 5
- Increase doses every 1-2 weeks for shorter half-life agents (sertraline, paroxetine) or 3-4 weeks for longer half-life agents (fluoxetine) 4
- Use standardized anxiety rating scales (GAD-7, HAM-A) to track response objectively
- If no response after 12 weeks at therapeutic doses, reassess diagnosis and consider switching to a different SSRI/SNRI or adding CBT 4
Emerging Evidence on Bupropion Combinations
Recent data suggest that naltrexone-bupropion ER may have modest anxiolytic effects in patients with depression and anxiety 9, though this combination is FDA-approved only for obesity. Similarly, dextromethorphan-bupropion is being studied for MDD with anxiety symptoms 10, but evidence remains preliminary. These are not recommended as first-line options for primary anxiety.
Bottom line: Bupropion monotherapy at 150 mg is inadequate for anxiety. Switch to an SSRI/SNRI as first-line treatment, or add one as adjunctive therapy if continuing bupropion is clinically justified. Avoid the temptation to simply increase the bupropion dose, as this may worsen anxiety symptoms.